title: [Results of treatment for male prolactinomas].
abstract: We evaluated the results of medical treatment for male prolactinomas. We encountered eight patients with male prolactinomas. The age was 25 to 54 years old (mean 43 years) and the chief clinical symptoms were visual acuity/field defect in three patients, pituitary apoplexy in one patient, disturbance of ejection in one patient, generalized convulsion in one patient, headache in one patient and general fatigue in one patient. The serum prolactin level was 279 to 7,360 ng/ml (mean 2,832 ng/ml). The tumors in all patients were large with a mean diameter of 34.9 mm (range, 21 to 43 mm). In only one patient, the operation was performed due to pituitary apoplexy. All the patients were treated by medication, with bromocriptine being used in seven patients and terguride in one. The follow-up period was 0.8 to 13 years (mean 5.9 years) and, in all patients, the medical treatment was continued. The tumor decreased in size in all patients and the serum prolactin level at the last follow-up observation was 0.5 to 70.5 ng/ml (mean 26.9 ng/ml). All the neurological symptoms disappeared in the early stage of treatment. As for the complications of medical treatment; in one patient, orthostatic hypotension occurred during the initial administration of bromocriptine and one patient suffered CSF leakage two months after the administration of bromocriptine, so the repair of the sella floor by transsphenoidal surgery was necessary. The medical treatment for male prolactinomas is effective for a long term and should be the primary treatment for the male prolactinomas. In conclusion, patients can maintain a good quality of life for a long time by using dopamine agonists.
authors.affiliation: Department of Neurosurgery, Osaka City General Hospital, 2-13-22 Miyakojima-hondori, Miyakojima-ku, Osaka-city, Osaka 534-0021, Japan.
authors.forename: Yoshiyasu
authors.initials: Y
authors.lastname: Iwai
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yamanaka
authors.forename: Tomoya
authors.initials: T
authors.lastname: Ishiguro
authors.forename: Toshie
authors.initials: T
authors.lastname: Morikawa
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Matsuzaka
authors.forename: Masaki
authors.initials: M
authors.lastname: Komiyama
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Yasui
mesh_terms: D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D006801:Humans; D008090:Lisuride / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010899:Pituitary Apoplexy / Q000188:drug therapy; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D018491:Dopamine Agonists; C006208:dironyl; D001971:Bromocriptine; D011388:Prolactin; D008090:Lisuride